Cancer Research Technology Limited

Astex Therapeutics Limited

Janssen Pharmaceutica Nv

Galapagos Nv

Kim Louise Hirst

Steven Howard

Mark Stuart Chambers

Wolfgang Schmidt

Martin James Inglis Andrews

Juha Andrew Clase

James Daniel Osborne

Jeffrey David St Denis

Rhian Sara Holvey

Benjamin David Cons

Christopher Norbert Johnson

Gianni Chessari

Ildiko Maria Buck

Bernard Thomas Golding

David Charles Rees

Ian Robert Hardcastle

Emiliano Tamanini

Paul John Edwards

Dale Robert Mitchell

Angus MacLeod

Celine Florence Cano

Duncan Charles Miller

Joanne Peach

Arwel Lewis

Benjamin Paul Whittaker

David Wyn Watson

Gregory Bar

Martin Edward Mäntylä Noble

Roger John Griffin

Philip Huxley

Veronique Birault

Clifford John Harris

Reginald Christophe Xavier Brys

Grégory Louis Joseph Bar

Brian Christopher Bishop

Giovanni Alessandro Tricarico

Darren James Dixon

Jonas Calleja Priede

Matthew James Gaunt

Meenakshi Sundaram Shanmugham

David Parry-Jones

Aaron Michael Dumas

Olga Raquel Pinto Santos Oliveira Roussel

Charlotte Mary Griffiths-Jones

Jeremy Peter Scott

David Cousin

Steven Douglas Hiscock

David John Nash

Peter Richard Mullens

Alan Richard Burns

Guillaume François Parra

Nicholas Paul Richards

Isabelle Anne Lemasson

Sarah Cully

Paul Edwards

The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them

The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity

Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity

Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following:  The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazo[-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

Growing community of inventors

Saffron Walden, United Kingdom

Kim Louise Hirst